Liquida Technlogies Receives Investment to Bolster Development of Vaccines | Bill & Melinda Gates Foundation

Share

Media contact

Telephone:

+1 206.709.3400

Email:

[email protected]

RESEARCH TRIANGLE PARK, N.C. — Liquidia Technologies today announced the Bill & Melinda Gates Foundation has made a $10 million program-related investment (PRI) in the company to support the development and commercialization of safer and more effective vaccines and therapeutics. This follows recent announcements of the first Liquidia clinical trial of its lead seasonal flu candidate (LIQ001) and a collaborative agreement with the PATH Malaria Vaccine Initiative (MVI).

“We are delighted the Gates Foundation has decided to join an outstanding group of investors that share our confidence in the potential of PRINT® technology to improve vaccine delivery and effectiveness,” said Neal Fowler, Chief Executive Officer at Liquidia. “As the field of vaccines continues to grow, success will be defined by our ability to produce and deliver highly efficacious therapies in quantities and costs that will support the global demand.”

Read the full press release
(PDF, 80KB, 2 pages)